'the'에 해당되는 글 7건

  1. 2011.03.19 Fit the Bill by CEOinIRVINE
  2. 2009.03.31 Statins Dethroned by CEOinIRVINE
  3. 2009.03.10 Staring Into The Abyss, A Bit Before Cansec by CEOinIRVINE
  4. 2008.12.20 2008 the year in style by CEOinIRVINE
  5. 2008.12.14 Look of the day by CEOinIRVINE
  6. 2008.11.27 Behind The Scenes by CEOinIRVINE
  7. 2008.11.17 How To Stay Cool On The Job by CEOinIRVINE

Fit the Bill

Vocabulary 2011. 3. 19. 04:08

 이런 표현 들어보셨나요?
 아마 미국에 사셨으면 당연 들어보셨을꺼 같구
 몇번 미국인이랑 대화를 섞을 때 들어보신 분들도 있을 것 같아요.


 저도 미국 온지가 오래 되지 않아서
 첨엔 무슨 소린가 하다가
 자주 듣다보니 그런뜻으로 쓰는구나 감은 오는데요
 

 대충 품질.적당한 것에 대한 형용 표현으로 전 많이 들었는데
 오늘 사전을 찾아보니
 
Verb 1. fit the bill - be what is needed or be good enough for what is required; "Does this restaurant fit the bill for the celebration?"
conform to, fit, meet - satisfy a condition or restriction; "Does this paper meet the requirements for the degree?"
Based on WordNet 3.0, Farlex clipart collection. © 2003-2008 Princeton University, Farlex Inc.

요렇게 나오네요
fill the bill 은 거의 들어보지 못했지만,
역시 같은 표현이라고 하고요

 정확히 구미에 맞는
 아주 딱 들어맞는 좋은

did you get fit the bill car?  이런 슬랭식으로 써도 되겠네요

^_^


'Vocabulary' 카테고리의 다른 글

double freeture - New Vocabulary  (0) 2009.02.25
laundry limbo - New Vocabulary  (0) 2009.02.25
Spicey Edit - New Vocabulary  (0) 2009.02.25
Useful Expression  (0) 2008.11.26
Savvy  (0) 2008.11.10
Posted by CEOinIRVINE
l

Statins Dethroned

Business 2009. 3. 31. 06:18

Cholesterol medicines are no longer the top-selling drugs in the U.S.


ORLANDO--An era is grinding to a halt, as the best-selling drugs in the world begin their slow extinction as a financial force.

Cholesterol-lowering medicines, known as statins, lost their position as the top-selling drugs in the U.S. last year, thanks to the fact that two top brands have lost patent protection and are being replaced by cheaper generics, according to industry consultants IMS Health (nyse: RX - news - people ). That is a huge shift. According to IMS, statins and other cholesterol drugs first became America's top-selling drugs in 1999. Between 1999 and 2008, the death rate from heart attacks fell 30%, and statins and other heart drugs get a lot of the credit.

With patents running out on old blockbusters and new medicines underperforming, drug companies are losing the appetite to do the big studies of thousands of patients that have been a major scientific driver of the blockbuster age. In 2008, cholesterol drug sales fell 12% to $14.5 billion.

"Is this area of pharmacology for cardiology dead?" says James Stein, a professor of medicine at the University of Wisconsin, Madison. "Have we maxed out with very powerful statins and excellent blood-pressure drugs? Is there going to be another cardiology blockbuster ever again?"

The buzz here at the annual meeting of the American College of Cardiology has been for a collection of old generics: a single capsule dubbed a "polypill" that some say could benefit the public health. Data are due out today.

The other big story is from a study that already made news twice. Last March, it was announced that Crestor from AstraZeneca (nyse: AZN - news - people ) cut the rate of heart attacks, strokes and deaths in patients with inflamed arteries, as measured by the c-reactive protein (CRP) blood test. Full results were presented last November.

Sales of Crestor jumped 30% to $3.6 billion last year, even as Lipitor from Pfizer (nyse: PFE - news - people ) and the Vytorin combo pill from Merck (nyse: MRK - news - people ) and Schering-Plough (nyse: SGP - news - people ) saw their sales drop, largely thanks to those results.

In that same study, Crestor also prevented clots in the veins that can lead to blocked circulation in the legs or, if dislodged, can wind up in the lungs, potentially killing the patient. There were only 90 of these events, called venuous thromboembolisms (VTE), in the study, but patients who got Crestor were only half as likely to get them.

Crestor and the other statins are thought of as cholesterol-lowering drugs. But though burst cholesterol plaque in the arteries causes the blood clots that lead to heart attacks and strokes, cholesterol plays no role in VTEs. Paul Ridker of Brigham & Women's Hospital, the lead scientist on the Crestor study and pioneer of using c-reactive protein to measure heart risk (he has a patent on it), argues that this provides even more proof of the key role of inflammation in statins' effectiveness. Other drugs that prevent VTE are blood-thinners, which inevitably cause risky increased bleeding.

Roger Blumenthal, director of cardiology at Johns Hopkins University, says that the VTE results are "very impressive." But although he screens for CRP, he says that he won't yet be using the test as cholesterol used, upping a patients' statin dose until the CRP goes down. "I don't think we're there yet," Blumenthal says.

So what about new drugs? There was one with some impressive data, but it only seems to highlight the changes in the drug industry further, because it came from a tiny, privately held firm called Corthera, not from a big pharma or even a publicly traded biotech.

The drug is called relaxin, and it is a hormone released in pregnancy that was discovered at the beginning of the Great Depression. Now the idea is to use it to combat acute heart failure. Pregnant women, the idea goes, are dramatically increasing their blood supply, and the same kinds of biological changes might help people whose hearts are not pumping hard enough.

Preliminary results were encouraging, and even showed a benefit on reducing deaths in one dose--although experts warn to view that as preliminary until a larger study is done. John Teerlink of the University of California, San Francisco, who headed the study, says he's optimistic relaxin will help patients' hearts without causing other, pregnancy-like effects such as weakened tendons. "I was intrigued but not convinced," says Clyde Yancy, director of the Baylor Heart and Vascular Institute in Dallas.

In the past, heart failure drugs that have helped patients feel better have sometimes not helped them--and have even hurt them--in the long run. The last attempt at a treatment for hospitalized heart failure patients, Natrecor, wound up having its use severely restricted by its maker, Johnson & Johnson (nyse: JNJ - news - people ). The drug is currently the subject of two whistle-blower suits in which former employees accuse J&J of improperly marketing Natrecor before it became controversial.

As a result of controversies like Natrecor, industry is on the defensive. For the first time in years, the bags handed out to doctors here at the ACC meeting are not branded with any drug or company name. Neither are the lanyards from which badges hang.

Worse yet, this same story is repeating itself across medicine. Cholesterol drugs were replaced at the top of the U.S. pharmaceutical sales charts by schizophrenia drugs like Zyprexa from Eli Lilly (nyse: LLY - news - people ) and Seroquel from AstraZeneca. Antipsychotics are nearing patent expiry too, and they are controversy magnets. A Harvard doctor who argued for their use in kids is under attack, and Astra is being accused of burying bad data on Seroquel.

Last week, the American Psychiatric Association decided to phase out drug-company sponsored lectures and meals at its annual meeting. And today, Eli Lilly's top hope for a new anti-psychotic failed in a clinical trial, a result that JPMorgan labeled "a major setback."





'Business' 카테고리의 다른 글

Why The Tax Rate Debate Is Irrelevant  (0) 2009.03.31
Why Rick Wagoner Had To Go  (0) 2009.03.31
GM  (0) 2009.03.14
Microsoft vows openness for mobile app store  (0) 2009.03.12
Android sales to outstrip iPhone by '12?  (0) 2009.03.10
Posted by CEOinIRVINE
l

Staring Into The Abyss, A Bit Before Cansec

I’m just going to come out and say it:  I miss packet craft.  Sure, we can always pull out Scapy, and slap amusing packets together, but everything interesting is always at the other layers.

Or is it?

For CanSecWest this year, I thought it’d be interesting to take a look at the realm of Deep  Packet Inspectors. It turns out we were doing a lot of this around 2000 through 2002, and then…well, sort of stopped.  So, in this year’s CanSecWest paper, “Staring Into The Abyss:  Revisiting Browser v. Middleware Attacks In The Era Of Deep Packet Inspection” (DOC, PDF), I’m taking another crack at the realm — and I’m seeing really interesting capabilities to fingerprint, bypass, and otherwise manipulate systems that watch from the middle of networks, using protocol emulation abilities that have been part of browsers and their plugin ecosystem from the very beginning.

Ah, but here’s where I need some help.  I’ve worked pretty closely with Robert Auger from Paypal, who just published his own paper, “Socket Capable Browser Plugins Result In Transparent Proxy Abuse”.  We independently discovered the HTTP component of this attack pattern, and as I describe in my paper, we’ve kind of forgotten just how much can be done against Active FTP Application Layer Gateways.

So, if I may ask, take a look, check out my paper, and if you have some thoughts, corrections, or interesting techniques, let me know so I can integrate them into my CanSecWest presentation.  Here’s the full summary, to whet your appetite:

DPI — Deep Packet Inspection — technology is driving large amounts of intelligence into the infrastructure, parsing more and more context from data flows going past. Though this work may be necessary to support important business and even security requirements, we know from the history of security that to parse data is to potentially be vulnerable to that data – especially when the parser is designed to extract context as quickly as possible. Indeed, companies such as BreakingPoint and Codenomicon have made their names building test tools to expose potential faults with DPI engines. But could anyone actually trigger these vulnerabilities? In this paper, we restart an old line of research from several years ago: The use of in-browser technologies to “tweak” Deep Packet Inspection systems.

Essentially, by controlling both endpoints surrounding a DPI system, possibly using the TCP (and sometimes UDP) socket code that plugins add to browsers, what behavior can we extract? We find three lines of attack worth noting.

First, firewalls and NATs — the most widely deployed packet inspectors on the Internet today — can still be made to open firewall holes to the Internet by having the browser trigger the Application Layer Gateway (ALG) for protocols like Active FTP. We extend older work by integrating mechanisms for acquiring the correct internal IP address of a client, necessary for triggering many inspection engines, we survey other protocols such as SIP and H.323 that have their own inspection engines, and we explore better strategies for triggering these vulnerabilities without socket engines from browser plugins. We also explore a potentially new mechanism, “Window Dribbling”, that allows an HTTP POST from a browser to be converted into a full bidirectional conversation by only allowing a remote sender to “dribble” a fixed number of bytes per segment.

Second, we (along with Robert Auger at Paypal) find that transparent HTTP proxies, such as Squid, will “override” the intended destination of browser sockets, allowing a remote attacker to send and receive data from arbitrary web sites. This allows (at minimum) extensive and expensive click fraud attacks, and may expose internal connectivity as well (HTTP or even TCP).

Third, and most interestingly, we find that active DPI’s — those that actually alter the flow of traffic between a client and a server — all seem to expose subtly different parsers and handlers for the protocols they manipulate. These variations of behavior can be remotely fingerprinted, allowing an attacker to identify DPI platforms so as to correctly target his attacks. This capability, understood particularly in light of Felix Lindner’s recent work on generic attacks against Cisco infrastructure, underscores the need for both DPI vendors to test their platforms extensively, and for IT managers to deploy critical infrastructure patches with at least as much vigor as desktop support receives today.

For remediation purposes, we recommend two lines of defense – one policy, one technical. As a matter of policy, we find the most important recommendation of this paper that industry reconsiders patching policies as they apply to infrastructure, especially as that infrastructure starts inspecting traffic at ever higher speeds in ever deeper ways. We are actively concerned that administrators have internalized the need to patch endpoints, but aren’t closely tracking the equipment that binds endpoints together – despite their ever increasing intelligence. This is as much a recommendation to vendors – to build patches quickly, and to code audit and fuzz with software from companies like Breakingpoint and Codenomicon – as it is a plea to IT departments to deploy the patches that are generated. Also from a policy perspective, while this paper does recognize the need for judicious use of DPI technology, systems that are deployed across organizational boundaries have particular need for correctness. There have been incidents in the past that have led to security vulnerability across entire ISPs.

On the technical front, we defend the existence of socket functionality in the browser, recognizing that constraining all networking to that which existed in 2001 is not leading to more stable or more secure networks. We explore a solution that potentially allow firewalls to integrate socket policies into their ALG’s, encouraging plugin developers to eventually join in with browser manufacturers and build a single, coherent, cross-domain communication standard. We also discuss more advanced transparent proxy caching policies, which will prevent the Same Origin Policy bypasses discussed above. Finally, we remind home router developers that browsers are still able to access their web interfaces from the Internet, and that this exposure can be repaired by tying default password effectiveness to either a button on the device or a power cycle.

The firewall fingerprinter should be online shortly, with source code for you to play with as well.  Thanks!

(Incidentally, yep, Source is this week, and I have something rather different in store for that event.  The times, they are busy.)

'Hacking' 카테고리의 다른 글

Intel CPU Architecture  (0) 2009.03.11
Socket Capable Browser Plugins Result In Transparent Proxy Abuse  (0) 2009.03.10
Apple Airport Extreme / Time Capsule Multiple Vulnerabilities  (0) 2009.03.07
DLL injection Wiki  (0) 2009.03.04
DLL Injection  (0) 2009.03.04
Posted by CEOinIRVINE
l

2008 the year in style

Fashion 2008. 12. 20. 15:53

'Fashion' 카테고리의 다른 글

Big Bend Theory  (0) 2009.02.10
Beauty Icon: Depression-Era Beauties  (0) 2008.12.20
“Celebrity Hairstyles Rihanna”  (0) 2008.12.20
Red Carpet  (0) 2008.12.20
Look of the day  (0) 2008.12.14
Posted by CEOinIRVINE
l

Look of the day

Fashion 2008. 12. 14. 13:36

'Fashion' 카테고리의 다른 글

“Celebrity Hairstyles Rihanna”  (0) 2008.12.20
Red Carpet  (0) 2008.12.20
Girly Girl  (0) 2008.12.14
tea time  (0) 2008.12.14
Roberto Cavalli  (0) 2008.12.14
Posted by CEOinIRVINE
l

Behind The Scenes

Fashion 2008. 11. 27. 04:41

'Fashion' 카테고리의 다른 글

Romio and Juliet  (0) 2008.11.28
Holiday Gift Guide  (0) 2008.11.28
Jesse Kamm  (0) 2008.11.27
Yves Saint Laurent Resort  (0) 2008.11.27
Power Shift: Michelle Obama  (0) 2008.11.27
Posted by CEOinIRVINE
l
pic
In Pictures:
Seven Work-Stress Relievers
Star Athletes On Staying Cool Under Pressure

Think you're stressed? Try a day in the life of Rich Gelfond, co-chief executive of IMAX, the large-format film company.

Take Nov. 5, for instance. After his usual 6 a.m. stint at the gym, Gelfond joined his board of directors and audit committee for a two-hour meeting. From there, he headed to a three-hour meeting to finalize third-quarter financials to be announced the next day. In the afternoon, he wrote a script for the conference call and practiced fielding tough questions with his public relations team, all while battle-planning with film executives preparing to launch Madagascar: Escape 2 Africa in 35 newly outfitted digital-projection Regal theaters--IMAX's (nasdaq: IMAX - news - people ) biggest opening to date.

That's pressure. But you don't need to be a top executive like Gelfond to feel stressed out on the job. The American Institute of Stress estimates that stress costs U.S. corporations $300 billion annually in health care costs, turnover and absenteeism.

In Pictures: Seven Work-Stress Relievers

In Pictures: 10 Star Atheletes On Staying Cool Under Pressure

How to cope? We spoke with psychologists and sports stars to find some helpful tactics--no heavy pharmaceuticals allowed. In calmer moments, much of this might seem like common sense. But if you think you've heard it all before, ask yourself: How often do you actually follow the advice?

In the short term, coping with stress is about finding release--or at least some semblance of it. When Gelfond is at his busiest--bouncing between meetings, grappling with the latest technology and dealing with investors--he makes sure he gets an hour in the gym before he starts his day. "Not only do [my workouts] help me to relieve existing stress, they increase my ability to deal with problems that arise throughout the day," he says.



'Business' 카테고리의 다른 글

SAP and Microsoft, Watch Your Back  (0) 2008.11.17
Top Republican senators oppose automaker bailout  (0) 2008.11.17
India's 40 Richest  (0) 2008.11.17
2009's Most Fuel-Efficient Vehicles  (0) 2008.11.17
Save the Planet, Save Some Cash  (0) 2008.11.17
Posted by CEOinIRVINE
l